Drugs / LP-184
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05933265 | Jun 2023 → Jul 2026 overdue | glioblastoma, metastatic neoplasm, non-small cell lung carcinoma, pancreatic adenocarcinoma +1 | Lantern Pharma Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933265 ↗ |
| Modality | Small molecule | “LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.” NCT05933265 ↗ |
| Route | Intravenous | “Eligible patients with advanced refractory solid tumors were enrolled to receive LP-184 intravenously on days 1 and 8 of each 21-day cycle.” PMID 42410111 ↗ Jul 2026 |